Interleukin-5 is the key cytokine in eosinophil differentiation and growth in the bone marrow and stimulates the release of eosinophils into the peripheral circulation. Thus, it is thought that IL-5 may be involved in the pathogenesis of hypereosinophilic syndromes (HES), a diverse group of poorly treated disorders characterized by sustained peripheral blood and/or tissue eosinophilia. Mepolizumab is a humanized monoclonal antibody to IL-5, and its safety and efficacy were assessed in this open-labelled trial. (more…)
Eosinophil infiltration of the mucosa is a feature of asthmatic airways. Their adhesion to bronchial epithelial cells has been ...
IgE plays an important role in allergic asthma. Reducing IgE in the airway mucosa should reduce airway inflammation. Omalizumab has ...
Lidocaine is a local anaesthetic that possesses the ability to potently shorten eosinophil survival. This study assessed the sa ...
Normally present at very low levels in plasma, antibodies of the immunoglobulin E (IgE) isotype were first discovered in 1967, ...
Tumour Necrosis Factor is a pro-inflammatory cytokine implicated in the pathogenesis of asthmatic airway inflammation, hyper-react ...